| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC3910 |
| Trial ID | NCT06464991 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | eque-cel|equecabtagene autoleucel|FUCASO |
| Location approved | China |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | A Phase III Randomized, Controlled Study of Equecabtagene Autoleucel Injection in Subjects With Lenalidomide-Refractory R/R Multiple Myeloma |
| Year | 2024 |
| Country | China |
| Company sponsor | Nanjing IASO Biotechnology Co., Ltd. |
| Other ID(s) | CT103AC004 |
| Cohort 1 | |||||||||||||
|
|||||||||||||